This study shows how AI can change the way drugs are made and delivered, making healthcare faster, more personalized, and cheaper.

Clarifies the potential role of vitamin D and kidney dysfunction in diabetic nephropathy through clinical and molecular analysis.

This study demonstrates interpretable, robust modeling for Parkinson’s telemonitoring, guiding reliable disease progression prediction under small-sample longitudinal data constraints.

The results demonstrate a strong link between vitamin D deficiency and an increased risk of coronary heart disease in adults.

AI-driven contrast mapping enhances voxel-level T2-MRI brain analysis, revealing phenotypic variations crucial for early diagnosis and neurodevelopmental profiling 

Integrating predictive analytics, reinforcement learning, and causal inference improves maternal outcomes by aligning risk prediction with real-time, equity-aware resource allocation decisions.

This review elucidates autoimmune mechanisms in Crohn’s disease, highlighting emerging molecular targets to advance precision immunotherapy and improve patient outcomes.

This study provides preliminary clinical evidence that standardized Orthosiphon stamineus extract may meaningfully reduce serum uric acid in hyperuricemic adults.

Bridges experimental and computational toxicology to enable predictive, human-relevant risk assessment frameworks for safer and faster chemical evaluation

This study integrates biomedical and ecological research, revealing shared biological mechanisms that inform therapeutic innovation, sustainable agriculture, and systems-level understanding of complex biological interactions.

This study demonstrates that dietary bioactive compounds play a significant role in reducing the risk of chronic diseases, improving cardiovascular health, and offering protective effects against certain types of cancer.

Multimodal, precision-guided angiogenic therapies—gene, cell, extracellular vesicle, and biomaterial-based—offer transformative potential for treating ischemic diseases where revascularization remains unfeasible.

Epigenetic clocks convert DNA methylation into a modifiable biomarker, repositioning ageing as a treatable clinical target.

Cellular reprogramming is transforming AMD care from symptom management toward genuine tissue replacement and repair.

Explains why highly accurate AI resistance models fail clinically, and outlines concrete validation, equity, and deployment fixes.

Spatial multi-omics repositions tissue context as a first-class clinical variable, but equitable, standardized translation remains unfinished business.

Spatial transcriptomics reveals disease architecture at cellular resolution, but cost, FFPE limits, and complexity keep it from routine clinical diagnostics.

Mapping senescent-cell heterogeneity to precision senotherapies could transform multimorbid, age-related disease treatment safely

Organoid-on-chip systems merge biological fidelity with engineering precision, offering AI-augmented, human-relevant platforms positioned to reshape preclinical drug development.

Bariatric-level pharmacotherapy now exists, yet muscle loss, rebound, cost, and pediatric uncertainty still limit its real-world promise.

Frailty-based, mechanism-anchored prescribing frameworks could replace single-disease guidelines that quietly harm complex older patients.

Cryo-EM and AlphaFold-era structural biology are converting Alzheimer’s tau, once undruggable, into a rationally targetable protein for next-generation therapeutics.

Extracellular vesicles promise cell-free precision diagnostics and therapeutics, but standardization, scalability, and regulatory gaps still block routine clinical adoption.

AI compresses AMR diagnosis and discovery timelines dramatically, yet no tool has reached regulatory clearance — validation and trust, not algorithms, remain the bottleneck.

Epigenome editing may silence sickle-globin defects without DNA cleavage, offering a safer, durable alternative to nuclease-based gene therapy.

Rationally engineered, actively targeted nanocarriers can close the ~0.7% tumor-delivery gap limiting nanomedicine efficacy in triple-negative breast cancer.

This review reframes chronic neurodegenerative and autoimmune disease through a reproducible, microbiome-centered mechanistic and therapeutic lens.

AMR is outpacing critical-care antibiotics; precision genomic, antibody, peptide, and nanozyme strategies may restore therapeutic options.

Composition-driven redesign of lipid nanoparticles can uncouple mRNA transfection from toxicity, enabling safer, thermostable, tissue-selective vaccines.

Intercellular mitochondrial transfer sustains tissue bioenergetics and immunity, offering a transformative, biologically grounded therapeutic strategy for degenerative and ischemic disease.

Reframing Long COVID as a biologically stratifiable network disorder could finally make targeted, effective treatment trials possible.

Novel antimicrobials show promise against multidrug-resistant infections in immunocompromised patients, yet gaps in stewardship, resistance, and equity persist.

Tissue-resident memory T cells permanently guard peripheral organs, but their dysregulation drives chronic autoimmune disease, making them a precise emerging therapeutic target.

Bridging barrier biology, nanomedicine, and physical delivery reveals why glioblastoma therapies still fail to reach infiltrative tumor margins.

STAG2/cohesin loss and oncofusion proteins collapse 3D chromatin loops in AML, silencing differentiation genes while revealing druggable, reversible epigenetic vulnerabilities.

This study highlights how prenatal endocrine disruptor exposure impairs neurodevelopment, emphasizing mixture effects, biological mechanisms, and urgent regulatory intervention needs.

Microneedle patches could replace injectable influenza vaccines, eliminate cold-chain dependence and needle-related barriers while enable equitable, self-administered global immunization.

Cellular senescence organizes IPF pathogenesis across cell types, positioning senotherapeutics and regenerative cell therapy as biologically grounded strategies for reversing, not merely slowing, fibrosis.

Smart, disease-triggered nanocarriers can concentrate rheumatoid arthritis drugs inside inflamed joints while sparing healthy tissue.

Integrating transcriptomic, epigenetic, and functional organoid data with genomics may finally close oncology’s persistent gap between diagnosis and matched treatment.

Mapping how ALS/FTD proteins phase-separate and solidify reveals shared biophysical vulnerabilities that could be therapeutically exploited across the disease spectrum.

Environmental exposures converge with genetic risk to trigger autoimmune flares, guiding precision prevention beyond genetics alone.

Ignoring sex and gender in drug research skews dosing, safety data, and treatment efficacy — precision medicine cannot ignore this variable.

AI-guided nanoparticle design shows real promise against pancreatic cancer's brutal biology, yet data, interpretability, and manufacturing gaps still block clinical translation.

Wearable digital biomarkers show strong clinical validity but require standardized validation, interoperable data systems, and equitable design before routine adoption.

Long-acting antiretrovirals could transform HIV into a truly manageable chronic disease — if health systems adapt equitably to deliver them.

Protein language models can resolve uncertain BRCA variants rapidly, potentially widening equitable access to PARP-inhibitor therapy worldwide.

Restoring mitochondrial-nuclear communication through PINK1/Parkin, Nrf2, and mitophagy pathways offers a unifying, druggable strategy for Parkinson's disease modification.

Artificial-intelligence risk models and digital twins could shift cardiology from reactive treatment toward proactive, individualized prevention — if bias, validation, and trust gaps are honestly addressed.

RNA modifications reprogram liver-cancer transcripts to drive growth, immune escape, and drug resistance—offering new biomarkers and druggable targets.

CRISPR editing could permanently correct Duchenne muscular dystrophy, but delivery, immunogenicity, and manufacturing barriers still limit safe clinical use.

Non-coding RNA networks orchestrate pancreatic cancer progression, immune evasion, and chemoresistance, revealing druggable nodes for precision therapy.

Lung-optimized lipid nanoparticles may finally deliver mutation-agnostic, curative gene editing to cystic fibrosis patients currently left without approved corrective therapy.

This review shows how artificial intelligence strengthens quality control and error detection in diagnostic laboratories, improving result accuracy, patient safety, and overall laboratory workflow efficiency.

This case highlights prolonged disease control after repeated metastasectomy and supports prospective evaluation of adjunctive Nuvastatic in metastatic colorectal cancer.

Integrating omics across molecular, cellular, organ and clinical scales may reveal sepsis endotypes that bedside scores miss, guiding precision therapy.

Covalent EGFR inhibitors succeed only when warhead reactivity and mutant selectivity are engineered as separate, complementary design problems.

Machine-learning ADMET screening moves antimalarial failure earlier and cheaper, sparing years of futile synthesis, animal testing and clinical expenditure.

Whole-cell phenotypic screening, rather than target-based design, offers the most credible route to durable new antibiotics against untreatable drug-resistant gonorrhoea.

Computationally designed multi-protein panels may detect cancer earlier, yet only rigorous validation, standardization, and regulatory alignment will realize that promise.

Integrating environmental exposome data with host genomics may reveal how prenatal and early-life exposures convert preleukemic clones into childhood leukaemia.